MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus valve balloon dilation catheter; AccuSniper, a double-layer balloon dilation catheter, Angelguide, an advanced pre-shaped ultra-hard guidewire; and AnchorMan, a left atrial appendage occlusion and guidance system. It also provides various active, mitral, and tricuspid valve products; left atrial appendage closure products; surgical accessories; low and high-voltage CRM products; leads and accessories; patient monitoring products; and arrhythmia diagnostic devices. In addition, the company offers clinical solutions, including aortic stenosis and atrial fibrillation-related stroke prevention. Further, it is involved in the manufacturing of raw materials for medical devices treating valvular heart diseases; and properties management. The company was founded in 2009 and is headquartered in Shanghai, China.
Research context
MicroPort CardioFlow Medtech Corporation appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
No comments yet
Start a focused discussion about 2160.HK.